🔗 Share this article

As the US continues making unprecedented adjustments to its immunization guidelines, an unexpected name has surfaced unexpectedly: Tracy Beth Høeg, an American of Danish descent physician and public health researcher who first made her name by casting doubt on COVID-19 vaccines in the pandemic and has concentrated on possible deaths following COVID-19 vaccination in her short position at the US Food and Drug Administration (FDA).

Planned Overhauls to Pediatric Vaccine Program

Health officials were set to announce sweeping changes to the pediatric vaccination calendar recently, bringing the US with the Danish national calendar, according to reports – a substantial departure that would place the US out of step with a large portion of the world with little proof for benefit. This reveal has been delayed until the next year.

In place of Vinay Prasad, Høeg is listed to speak at the event. She was just designated temporary leader of the FDA’s CDER, the fifth person to head the center this year.

A New Direction at the Regulatory Body

The acting appointment could signify a closer partnership between the pharmaceutical and biologics branches as Høeg and Dr. Prasad consolidate power at the FDA – and it points to a greater focus upon rolling back already-approved vaccines at the FDA.

Dr. Høeg has often pushed for halting some pediatric shot schedules in the US in order to be more in line with the Danish model, a country with universal health coverage and a number of inhabitants about the size of the state of Wisconsin.

To date comments, she has kept her attention on immunizations – traditionally the domain of Prasad, chief of the FDA’s vaccine center – rather than drug regulation.

Doubts Over Qualifications

Dr. Høeg has no obvious experience in drug development, approval processes or management, which has been typical for previous leaders of the biologics center. She has served at the FDA as a senior adviser to the agency head and CBER since March.

“She doesn’t seem to have the requisite experience” for running the pharmaceutical oversight division, remarked Jonathan Howard. “She has not conducted a scientific study. She is not versed in running a sizeable institution. She has no expertise in industry regulation.”

Past commissioners of the center would “understand laws and regulations and the research of pharmaceutical innovation”, commented Dr. Janet Woodcock. “Frankly, she has not acquired the kind of background that previous people who led the center have had.”

The drug center has an immense workload at the agency, the former commissioner stated.

“Everybody just focuses on the novel medication approvals, but the generic program clears thousands of off-brand pharmaceuticals. There’s a biosimilars program, over-the-counter program and other areas, and every single one have to be looked after,” Dr. Woodcock explained. “The thing you neglect, that’s the thing that I always told people is going to come back to haunt you.”

Additionally, a major administrative aspect to the job, which manages over 5,000 employees. “It’s a enormous leadership role, if you execute it properly,” the former official concluded.

Official Statement and Disputed Policies

Regarding inquiries about Dr. Høeg's credentials and whether this selection signifies increased cooperation among FDA leaders on vaccines, a spokesperson responded that the “concerns rely on inaccurate presumptions”.

“Her resume aligns with the responsibilities of her job,” the official said, citing the months Dr. Høeg spent advising the FDA commissioner on “drug safety and approval science, including computational safety modeling and immunization monitoring”.

As the temporary head, Dr. Høeg assumes responsibility for the commissioner’s new priority voucher program, a contentious one-day medication authorization process that allegedly concerned her former heads. “How are these drugs being chosen for this voucher program? Who is making the choices?” Howard asked. “There is a lot of confidentiality going on at the FDA right now.”

Broadly speaking, he remarked, “the Food and Drug Administration seems to be moving towards laxer oversight of all drugs, with the exception of vaccines.”

Established Past Work on Vaccines

With immunizations, Høeg has a more established, if problematic, track record, critics observe. She authored a analysis using unverified crowd-sourced reports to assess the rate of heart inflammation after COVID-19 immunization. She counseled the state of Florida chief medical officer Joseph Ladapo, who was said to have modified findings to indicate Covid vaccines are riskier than they are.

Among her “policy goals” for the new government included revising guidelines for recently developed shots and ending “optional” vaccines, she said post-election on a podcast. At the agency, Høeg has allegedly floated the idea of excluding young men from obtaining Covid vaccinations.

“She is an all-around ideologue who starts off with her conclusions and works backwards to retrofit the data in a highly disingenuous, dishonest fashion,” Howard said.

Taking Control and a “Push for Payback”

Dr. Høeg joined fellow dissenters, {like|